Atorvastatin increases endoglin, SMAD2, phosphorylated SMAD2/3 and eNOS expression in ApoE/LDLR double knockout mice

Journal of Atherosclerosis and Thrombosis

Volumn 16, Issue 3, 2009, Pages 265-274

  Nachtigal, Petr ^a   Pospisilova, Nada ^a   Vecerova, Lenka ^a   Micuda, Stanislav ^b   Brcakova, Eva ^b   Pospectova, Katerina ^a   Semecky, Vladimir ^a  

^a Charles University in Prague Faculty of Pharmacy   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

ApoE LDLR double knockout mice; Atorvastatin; Endoglin; eNOS; Phosphorylated SMAD2 3; SMAD2

Indexed keywords

APOLIPOPROTEIN E; ATORVASTATIN; CHOLESTEROL; ENDOGLIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; SMAD2 PROTEIN; SMAD3 PROTEIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; DIETARY INTAKE; FEMALE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; VASCULAR ENDOTHELIUM; WESTERN BLOTTING;

EID: 70350225475     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.E745     Document Type: Article

References (32)

1. Guerrero-Esteo M, Lastres P, Letamend-acia A, Pérez-Alvarez MJ, Langa C, López LA, Fabra A, García-Pardo A, Vera S, Letarte M, Bernabéu C: Endoglin overexpression modulates cellular morphology, migration, and adhesion of mouse fibroblasts. Eur J Cell Biol, 1999; 78:614-623
2. Zhang H, Shaw AR, Mak A, Letarte M: Endoglin is a component of the transforming growth factor (TGF)-beta receptor complex of human pre-B leukemic cells. J Immunol, 1996; 156:564-573
3. Behr-Roussel D, Rupin A, Simonet S, Bonhomme E, Coumailleau S, Cordi A, Serkiz B, Fabiani JN, Verbeuren TJ: Effect of chronic treatment with the inducible nitric oxide synthase inhibitor N-iminoethyl-L-lysine or with L-arginine on progression of coronary and aortic atherosclerosis in hypercholesterolemic rabbits. Circulation, 2000; 102:1033-1038
4. Conley BA, Smith JD, Guerrero-Esteo M, Bernabeu C, Vary CP: Endoglin, a TGF-beta receptor-associated protein, is expressed by smooth muscle cells in human atherosclerotic plaques. Atherosclerosis, 2000; 153:323-335
5. Lebrin F, Deckers M, Bertolino P, Ten Dijke P: TGF-beta receptor function in the endothelium. Cardiovasc Res, 2005; 65:599-608
6. Nachtigal P, Jamborova G, Pospisilova N, Pospechova K, Solichova D, Zdansky P, Semecky V: Atorvastatin has distinct effects on endothelial markers in different mouse models of atherosclerosis. J Pharm Pharm Sci, 2006; 9:222-230
7. Nachtigal P, Pospisilova N, Jamborova G, Pospechova K, Solichova D, Andrys C, Zdansky P, Semecky V: Endothelial expression of endoglin in normocholesterolemic and hypercholesterolemic C57BL/6J mice before and after atorvastatin treatment. Can J Physiol Pharmacol, 2007; 85:767-773
8. Piao M, Tokunaga O: Significant expression of endoglin (CD105), TGFbeta-1 and TGFbeta R-2 in the atherosclerotic aorta: an immunohistological study. J Atheroscler Thromb, 2006; 13:82-89
9. Lahera V, Goicoechea M, de Vinuesa SG, Miana M, de las Heras N, Cachofeiro V, Luno J: Endothelial dysfunction, oxidative stress and inflammation in atherosclerosis: beneficial effects of statins. Curr Med Chem, 2007; 14:243-248
10. Sessa WC: eNOS at a glance. J Cell Sci, 2004; 117:2427-2429
11. Mungrue IN, Bredt DS, Stewart DJ, Husain M: From molecules to mammals: what's NOS got to do with it? Acta Physiol Scand, 2003; 179:123-135
12. Schönbeck U, Libby P: Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? Circulation, 2004; 109:II 18-26
13. Nachtigal P, Pospisilova N, Pospechova K, Jamborova G, Kopecky M, Jaynes R, Briestensky J, Santar I, Smahelova A, Solichova D, Zdansky P, Semecky V: MDOC and atorvastatin have potential antiinflammatory effects in vascular endothelium of apoE-/- mouse model of atherosclerosis. Life Sci, 2006; 78:1983-1989
14. Schalkwijk CG, van Dam B, Stehouwer CD, van Hinsbergh VW: Mevastatin increases eNO synthase expression and inhibits lipid peroxidation in human endothelial cells. Clin Hemorheol Microcirc, 2007; 37:179-184
15. Jerkic M, Rivas-Elena JV, Prieto M, Carrón R, Sanz-Rodríguez F, Pérez-Barriocanal F, Rodríguez-Barbero A, Bernabéu C, López-Novoa JM: Endoglin regulates nitric oxide-dependent vasodilatation. FASEB J, 2004; 18:609-611
16. Santibanez JF, Letamendia A, Perez-Barriocanal F, Silvestri C, Saura M, Vary CP, Lopez-Novoa JM, Attisano L, Bernabeu C: Endoglin increases eNOS expression by modulating Smad2 protein levels and Smad2-dependent TGF-beta signaling. J Cell Physiol, 2007; 210:456-468
17. Zadelaar S, Kleemann R, Verschuren L, de Vries-Van der Weij J, van der Hoorn J, Princen HM, Kooistra T: Mouse models for atherosclerosis and pharmaceutical modifiers. Arterioscler Thromb Vasc Biol, 2007; 27:1706-1721
18. Nachtigal P, Pospisilova N, Jamborova G, Pospechova K, Solichova D, Andrys C, Zdansky P, Micuda S, Semecky V: Atorvastatin has hypolipidemic and anti-inflammatory effects in apoE/LDL receptor-double-knockout mice. Life Sci, 2008; 82:708-717
19. Letamendía A, Lastres P, Botella LM, Raab U, Langa C, Velasco B, Attisano L, Bernabeu C: Role of endoglin in cellular responses to transforming growth factor-beta. A comparative study with betaglycan. J Biol Chem, 1998; 273:33011-33019
20. Ma X, Labinaz M, Goldstein J, Miller H, Keon WJ, Letarte M, O'Brien E: Endoglin is overexpressed after arterial injury and is required for transforming growth factor-beta-induced inhibition of smooth muscle cell migration. Arterioscler Thromb Vasc Biol, 2000; 20:2546-2552
21. Li C, Mollahan P, Baguneid MS, McMahon RF, Kumar P, Walker MG, Freemont AJ, Kumar S: A comparative study of neovascularisation in atherosclerotic plaques using CD31, CD105 and TGF beta 1. Pathobiology, 2006; 73:192-197
22. Pospisilova N, Semecky V, Jamborova G, Pospechova K, Solichova D, Andrys C, Zdansky P, Nachtigal P: Endoglin expression in hyper-cholesterolemia and after atorvastatin treatment in apoE-deficient mice. J Pharm Pharm Sci, 2006; 9:388-397
23. Toporsian M, Gros R, Kabir MG, Vera S, Govindaraju K, Eidelman DH, Husain M, Letarte M: A role for endoglin in coupling eNOS activity and regulating vascular tone revealed in hereditary hemorrhagic telangiectasia. Circ Res, 2005; 96:684-692
24. Bobik A: Transforming growth factor-betas and vascular disorders. Arterioscler Thromb Vasc Biol, 2006; 26:1712-1720
25. Chen CL, Huang SS, Huang JS: Cholesterol modulates cellular TGF-beta responsiveness by altering TGF-beta binding to TGF-beta receptors. J Cell Physiol, 2008; 215:223-233
26. Chen CL, Liu IH, Fliesler SJ, Han X, Huang SS, Huang JS: Cholesterol suppresses cellular TGF-beta responsiveness: implications in atherogenesis. J Cell Sci, 2007; 120:3509-3521
27. Mallat Z, Tedgui A: The role of transforming growth factor beta in atherosclerosis: novel insights and future perspectives. Curr Opin Lipidol, 2002; 13:523-529
28. Feinberg MW, Jain MK: Role of transforming growth factor-beta1/Smads in regulating vascular inflammation and atherogenesis. Panminerva Med, 2005; 47:169-186
29. Saura M, Zaragoza C, Cao W, Bao C, Rodríguez-Puyol M, Rodríguez-Puyol D, Lowenstein CJ: Smad2 mediates transforming growth factor-beta induction of endothelial nitric oxide synthase expression. Circ Res, 2002; 91:806-813
30. Blanco FJ, Santibanez JF, Guerrero-Esteo M, Langa C, Vary CP, Bernabeu C: Interaction and functional interplay between endoglin and ALK-1, two components of the endothelial transforming growth factor-beta receptor complex. J Cell Physiol, 2005; 204:574-584
31. Blair A, Shaul PW, Yuhanna IS, Conrad PA, Smart EJ: Oxidized low density lipoprotein displaces endothelial nitric-oxide synthase (eNOS) from plasmalemmal caveolae and impairs eNOS activation. J Biol Chem, 1999; 274:32512-32519
32. Laufs U, La Fata V, Plutzky J, Liao JK: Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation, 1998; 97:1129-1135